1. Home
  2. TNXP vs LAES Comparison

TNXP vs LAES Comparison

Compare TNXP & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$11.71

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$2.25

Market Cap

675.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
LAES
Founded
2007
2022
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
675.0M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
TNXP
LAES
Price
$11.71
$2.25
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
413.1K
6.2M
Earning Date
05-11-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
$93.36
Revenue Next Year
$38.29
$43.06
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$1.99
52 Week High
$29.19
$8.71

Technical Indicators

Market Signals
Indicator
TNXP
LAES
Relative Strength Index (RSI) 38.76 38.15
Support Level $9.72 $2.22
Resistance Level $13.36 $2.64
Average True Range (ATR) 0.73 0.09
MACD -0.25 -0.01
Stochastic Oscillator 4.81 11.43

Price Performance

Historical Comparison
TNXP
LAES

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

Share on Social Networks: